SOPHiA GENETICS (NASDAQ:SOPH) Shares Down 5% – Should You Sell?

SOPHiA GENETICS SA (NASDAQ:SOPH) shares dropped 5% during trading on Friday . The company traded as low as $8.45 and last traded at $8.47. Approximately 32,677 shares were traded during trading, a decline of 87% from the average session volume of 242,677 shares. The stock had previously closed at $8.92.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. HC Wainwright increased their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Stock Down 9.3%

The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a market cap of $678.71 million, a P/E ratio of -7.03 and a beta of 0.96. The company’s 50-day simple moving average is $6.46 and its 200 day simple moving average is $5.43.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. Research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other SOPHiA GENETICS news, insider Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $7.52, for a total value of $30,080.00. Following the sale, the insider owned 586,887 shares in the company, valued at $4,413,390.24. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $8.80, for a total transaction of $44,000.00. Following the sale, the chief technology officer owned 172,171 shares of the company’s stock, valued at approximately $1,515,104.80. This represents a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 334,842 shares of company stock worth $2,110,215. 4.88% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

Large investors have recently made changes to their positions in the stock. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS in the first quarter valued at $50,000. Squarepoint Ops LLC acquired a new position in SOPHiA GENETICS during the 3rd quarter valued at about $49,000. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the fourth quarter worth about $49,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS in the 4th quarter valued at about $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS during the 4th quarter valued at about $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.